ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of va...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingor, Paul, Weber, Markus, Camu, William, Friede, Tim, Hilgers, Reinhard, Leha, Andreas, Neuwirth, Christoph, Günther, René, Benatar, Michael, Kuzma-Kozakiewicz, Magdalena, Bidner, Helen, Blankenstein, Christiane, Frontini, Roberto, Ludolph, Albert, Koch, Jan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446974/
https://www.ncbi.nlm.nih.gov/pubmed/30972018
http://dx.doi.org/10.3389/fneur.2019.00293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446974/
https://www.ncbi.nlm.nih.gov/pubmed/30972018
http://dx.doi.org/10.3389/fneur.2019.00293

Ejemplares similares